{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:10:12Z","timestamp":1761491412442,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,4,28]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>The use of immune checkpoint inhibitors is increasing in clinical practice. While they have provided significant benefit to many patients, a new category of adverse effects, immune-related adverse effects, has emerged with their use. These effects can range from mild to severe and affect nearly every organ system. A man in his 70swith metastatic gastro-oesophageal junction adenocarcinoma who received one cycle of third-line pembrolizumab presented after three episodes of transient left facial paresthesia, the last of which extended to the left extremities and disturbed peripheral vision of the left eye. He was found to have subclinical seizures and cerebrospinal fluid positive for Ma2\/Ta paraneoplastic antibodies, consistent with paraneoplastic limbic encephalitis. We describe an unusual presentation of paraneoplastic limbic encephalitis. This case adds to the limited literature describing the association of paraneoplastic limbic encephalitis and treatment with immune checkpoint inhibitors as well as the observed associations with immune-related adverse events and treatment responses.<\/jats:p>","DOI":"10.1136\/bcr-2021-247676","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T12:16:41Z","timestamp":1653394601000},"page":"e247676","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-5848","authenticated-orcid":false,"given":"Lauren","family":"Laderman","sequence":"first","affiliation":[{"name":"Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Naveed","sequence":"additional","affiliation":[{"name":"Department of Neurology, Temple University Health System Inc, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"LoPinto-Khoury","sequence":"additional","affiliation":[{"name":"Department of Neurology, Temple University Health System Inc, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Miron","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"2025082703371063000_15.5.e247676.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"2025082703371063000_15.5.e247676.2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025082703371063000_15.5.e247676.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2025082703371063000_15.5.e247676.4","doi-asserted-by":"crossref","unstructured":"Janjigian YY . KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG\/GEJC): a double-blind, randomized, placebo-controlled phase 3 study. J Clin Oncol 2019;87.doi:10.1200\/JCO.2019.37.15_suppl.TPS4146","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4146"},{"key":"2025082703371063000_15.5.e247676.5","doi-asserted-by":"publisher","DOI":"10.1001\/j amaoncol.2018.0013"},{"key":"2025082703371063000_15.5.e247676.6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","journal-title":"Future Oncol"},{"key":"2025082703371063000_15.5.e247676.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"2025082703371063000_15.5.e247676.8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","article-title":"Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients","volume":"123 (Pt 7","author":"Gultekin","year":"2000","journal-title":"Brain"},{"key":"2025082703371063000_15.5.e247676.9","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181548"},{"key":"2025082703371063000_15.5.e247676.10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/brain\/120.6.923","article-title":"Limbic encephalitis and small cell lung cancer. Clinical and immunological features","volume":"120 (Pt 6","author":"Alamowitch","year":"1997","journal-title":"Brain"},{"key":"2025082703371063000_15.5.e247676.11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"2025082703371063000_15.5.e247676.12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab Therapy\u2014Review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"JCM"},{"key":"2025082703371063000_15.5.e247676.13","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215012","article-title":"Limbic encephalitis following immunotherapy against metastatic malignant melanoma","volume":"2016","author":"Salam","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2025082703371063000_15.5.e247676.14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604"},{"key":"2025082703371063000_15.5.e247676.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"2025082703371063000_15.5.e247676.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025082703371063000_15.5.e247676.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01266.x"},{"key":"2025082703371063000_15.5.e247676.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70282-5"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-247676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:37:18Z","timestamp":1756291038000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-247676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,24]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bcr-2021-247676"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-247676","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}